Note
- 1. presentazioni, poster e abstract segnati con uno o due asterischi sono, a mio avviso, da seguire con attenzione;
2. tralascio al momento sia le presentazioni sia i poster dedicati a complicanze e problemi patogenetici.
La mia prima lettura del
PROGRAM AT A GLANCE vede:
Workshop for New Investigators – lunedì
1
A Path to an HIV Vaccine
Galit Alter - Ragon Institute of MGH , MIT and Harvard, Cambridge, MA, US
2
Animal Models of HIV Prevention and Cure
Guido Silvestri - Emory University, Decatur, GA, US
4
** Pathogenesis of HIV Complications
Peter W. Hunt - University of California San Francisco, San Francisco, CA, US
5
** HIV Cure Research
John M. Coffin - Tufts University, Boston, MA, US
Specific HIV Integration Sites Linked to Clonal Expansion and Persistence of Cells (Plenary Session) – lunedì
21
Specific HIV Integration Sites Linked to Clonal Expansion and Persistence of Cells
Stephen H. Hughes - National Cancer Institute, Frederick, MD, US
N’Galy-Mann Lecture - lunedì
19
* Antiretroviral Therapy: Past, Present, and Future
David A. Cooper - Kirby Institute, University of New South Wales, Sydney, Australia
New Discoveries in HIV Pathogenesis (Oral Abstracts) – lunedì
47
Inflammation Persists Despite Early Initiation of ART in Acute HIV Infection
Netanya S. Utay - University of Texas Medical Branch at Galveston,Texas, US
48
HIV Burden and Biomarker Associations With Colonic HIV RNA During Acute HIV Infection
Trevor A. Crowell - On behalf of the RV254/SEARCH010 Study Group - US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, US
49
Identification and Characterization of Individual HIV-Infected CD4 T Cells Ex Vivo
Joseph Casazza - Vaccine Research Center, NIAID, NIH, Bethesda, MD, US
50
* Efficacy of HIV-1 Monoclonal Antibody Immunotherapy in Acute SHIV-Infected Macaques
Diane L. - US Military HIV Research Program, Silver Spring, MD, US
51
HIV-1 Infections With Multiple Founders Are Associated With Higher Viral Loads
Morgane Rolland - On behalf of the Step/HVTN502 and RV144 study teams - Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US
52
** Post-Treatment Controllers Have Particular NK Cells With High Anti-HIV Capacity: VISCONTI Study
Daniel Scott-Algara - Institut Pasteur, Paris, France
53
*Antiretroviral Therapy Preserves Polyfunctional HIV-1–Specific CD8 T Cells With Stem-Cell–Like Properties
Selena Vigano - The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, US
Leaky Latency (Themed Discussion) - lunedì
392
** Defective HIV-1 Proviruses Can Be Transcribed Upon Activation
Ya-Chi Ho - Johns Hopkins University School of Medicine, Baltimore, MD, US
379
Characterizing the Active HIV Reservoir on ART: Cell- Associated HIV RNA and Viremia
Feiyu Hong - University of Pittsburgh, Pittsburgh, PA, US
390
Nascent LTR-Driven Transcription Can Lead to Translation of HIV Proteins in Resting CD4+ T Cells
Laura DeMaster - University of Pennsylvania, Philadelphia, US
Harnessing Antibodies for Prevention and Therapeutics (Symposium) - lunedì
66
Immunoprophylaxis by Gene Transfer: Shortcut to an HIV Vaccine
Phil Johnson - Children’s Hospital of Philadelphia, Philiadlphia, PA, US
67
** Broadly Neutralizing Antibodies for HIV-1 Eradication Strategies
Dan H. Barouch - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US
New Insights Into HIV Persistence, Latency Reversal, and Viremia Rebound (Oral Abstracts) - mercoledì
104LB
Durable Control of Viral Rebound in Humanized Mice by ABX464 Targeting Rev Functions
Jamal Tazi - University of Montpellier, Montpellier, France
106
* Analysis of HIV RNA in Single Cells Reveals Clonal Expansions and Defective Genomes
Mary F. Kearney - National Cancer Institute, Frederick, MD, MD, US
107
* Low-Level HIV Viremias Originate in Part From Infected Proliferating Cells
Marta E. Bull - University of Washington, Seattle, WA, US
108
* Treatment With a TLR7 Agonist Induces Transient Viremia in SIV-Infected ART-Suppressed Monkeys
James B. Whitney - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US
109
** Panobinostat Broadly Activates Latent HIV-1 Proviruses in Patients
Sarah E. Palmer - Westmead Millennium Institute and University of Sydney, Westmead, Australia
110LB
* The Size of the Active HIV Reservoir Predicts Timing of Viral Rebound
Jonathan Li - Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, US
111LB
* Biomarkers to Predict Viral Rebound at Antiretroviral Therapy Interruption in SPARTAC
John Frater - On behalf of the SPARTAC Trial Investigators - University of Oxford, Oxford, United Kingdom
112LB
HIV-1 Diversity and Tropism of Rebound Virus After Treatment Discontinuation
Maria M. Bednar - On behalf of the NWCS 379 team - University of North Carolina, Durham, NC, US
New Antiretroviral Agents, Strategies, and HIV Drug Resistance (Oral Abstracts) - mercoledì
113LB
* Tenofovir Alafenamide (TAF) in a Single-Tablet Regimen in Initial HIV-1 Therapy
David Wohl - University of North Carolina, Chapel Hill, NC, US
114LB
* Antiviral Activity/Safety of a Second- Generation HIV-1 Maturation Inhibitor
Max Lataillade - Bristol-Myers Squibb, Wallingford, CT, US
I POSTER CHE MI PAIONO PIÙ IMPORTANTI:
368
** Stimulation of Broad CTL Response Is Required to Clear Latent HIV-1 in Humanized Mice
Liang Shan - Yale University, New Haven, CT, US
369
* In vivo effects of Panobinostat and Romidepsin on HIV-1-specific CD8 T Cell Immunity
Rikke Olesen - Aarhus University Hospital, Aarhus, Denmark
371
* Blockade of PD-L1 Does Not Reverse HIV Latency in CD4+ T Cells Ex Vivo
Elizabeth Fyne - University of Pittsburgh, Pittsburgh, PA, US
372
** Impact of HIV Latency Reversing Agents on Natural Killer Cells
Carolina Garrido - University of North Carolina, Chapel Hill, NC, US
373
The Earlier cART Is Initiated During PHI, the More Intracellular HIV-DNA Decreases
Moussa Laanani - On behalf of the ANRS PRIMO Cohort Study Group - APHP, Bicêtre Hospital, Le Kremlin-Bicêtre, France
376
Stable Total HIV-1 DNA Levels Prior and Post ART Interruption in Chronic HIV
Emmanouil Papasavvas - The Wistar Institute, Philadelphia, PA, US
377
Aviremia 10-Year Post-ART Discontinuation Initiated at Seroconversion
Sabine I. Kinloch - University College London, London, United Kingdom
378
Identifying HIV Variants that Rebound after Treatment Interruption
Jonathan Z. Li - Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US
380
Liver Macrophages and HIV-1 Persistence
Abraham J. Kandathil - Johns Hopkins School of Medicine, Baltimore, MD, US
San Francisco, San Francisco, CA, US
381
Large-Scale Analysis of HIV-1 Integration Sites in Untreated and Treated Patients
Diana Schenkwein- National Center for Tumor Diseases; German Cancer Research Center, Heidelberg, Germany
383
Long-Term Effect of Temporary ART During Primary HIV Infection on the Viral Reservoir
Alexander Pasternak - Academic Medical Center University of Amsterdam, Amsterdam, Netherlands
387
Selectively Eliminating HIV Latently Infected Cells Without Viral Reactivation
Grant R. Campbell - University of California San Diego, La Jolla, CA, US
388
* PD1 Identifies Latently HIV-Infected Nonproliferating and Proliferating CD4+ T Cells
Renee M. van der Sluis - Doherty Institute, Melbourne University, Melbourne, Australia
389LB
2B4+PD1+ Naïve and Memory CD4+ T Cells Are Associated With Residual Viremia on ART
Bernard J. Macatangay - University of Pittsburgh, Pittsburgh, PA, US
390
Nascent LTR-Driven Transcription Can Lead to Translation of HIV Proteins in Resting CD4+ T Cells
Laura DeMaster - University of Pennsylvania, Philadelphia, PA, US
391
Influenza Vaccination Increases HIV-1 Transcription During Antiretroviral Therapy
Christina C. Yek - University of California San Diego, San Diego, CA, US
392
** Defective HIV-1 Proviruses Can Be Transcribed Upon Activation
Ya-Chi Ho - Johns Hopkins University School of Medicine, Baltimore, MD, US
394
* Variable HIV Replication Competency Following Latency Disruption in CD4+ T Cells
Jason M. Hataye - National Institute of Allergy and Infectious Diseases, Bethesda, MD, US
397
** Multiple Rounds of T-Cell Activation Induce Additional HIV-1 From the Latent Reservoir
Nina N. Hosmane - Johns Hopkins University School of Medicine, Baltimore, MD, US
398
* The Inducible HIV-1 Reservoir Predicted by Combinations of pre- and on-ART Parameters
Anthony R. Cillo - University of Pittsburgh, Pittsburgh, PA, US
400
* Targeted Disruption of Essential HIV-1 Proviral Genes by Rare-Cutting Endonucleases
Keith R. Jerome - Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US
401
Enhancing Anti-HIV Gene Therapy: Combining MegaTAL Nuclease Gene Editing With Selection Cassettes
Biswajit Paul - Fred Hutchinson Cancer Research Center, University of Washington, Seattle
402
* A Phase I Clinical Trial of Autologous CD4+ T Cells Modified With a Retroviral Vector Expressing the MazF Endoribonuclease in Patients With HIV-1
Jeffrey M. Jacobson - Drexel University College of Medicine, Philadelphia, PA, US
403
* CRISPRs Are Able to Efficiently Target Latent HIV and Halt New Infections
Monique Nijhuis - University Medical Center Utrecht, Utrecht, Netherlands
405
Panobinostat Dosing Has Broad but Transient Immunomodulatory Effects in HIV Patients
Martin Tolstrup - Aarhus University Hospital, Aarhus, Denmark
406
Multi-Dose Romidepsin in SIV-Infected RMs Reactivates Latent Virus in Absence of ART
Benjamin Policicchio - University of Pittsburgh, Pittsburgh, PA, US
407
Suberanilohydroxamic Acid (SAHA)-Induced Histone Modifications in the HIV Promoter in a Human, Primary CD4 T Cell Model of Latency
Brian Reardon - University of California San Diego, La Jolla, CA, US
409
* Off-Target Effects of SAHA May Inhibit HIV Activation
Cory H. White - University of California San Diego, La Jolla, CA, US
410
* Bystander Effect of Histone Deacetylase Inhibitors on HIV-1 Infection
Grant R. Campbell - University of California San Diego, La Jolla, CA, US
413
* Targeting HIV-1 Latency With a Potent Tat Inhibitor
Susana T. Valente - The Scripps Reasearch institute, Jupiter, FL, US
415
** Immune Modulation With Rapamycin as a Potential Strategy for HIV-1 Eradication
Alyssa R. Martin - Johns Hopkins University School of Medicine, Baltimore, MD, US
416
** Latency Reversing Agents Activate Latent Reservoirs in the Brain of SIV-Infected Macaques
Lucio Gama - Johns Hopkins University School of Medicine, Baltimore, MD, US
417
* TLR7 Agonist GS-9620 Activates HIV-1 in PBMCs From HIV-Infected Patients on cART
Derek D. Sloan - Gilead Sciences, Inc., Foster City, CA, US
418
Baracitinib, Ruxolitinib, Dasatinib Block HIV Replication, Activation, Reactivation
Christina Gavegnano - Emory University, Atlanta, GA, US
419
* Ex Vivo Identification of Highly Effective Latency- Reversing Drug Combinations
Gregory M. Laird - Johns Hopkins University School of Medicine, Baltimore, MD, US
425
CD4+ Tissue-Resident Memory T Cells Are an Important Reservoir for HIV Persistence
Angela R. Wahl - University of North Carolina, Chapel Hill, NC, US
428LB
* Short-Term Disulfiram to Reverse Latent HIV Infection: A Dose Escalation Study
Julian H. Elliott - on behalf of the Disulfiram Study investigators - Monash University/Alfred Hospital, Melbourne, Australia
Drug Development (Poster Session) – poster
# 536, 537, 538, 540, 542.
ART: Recent Perspectives (Poster Session) – poster
# 544, 545, 554LB.